Document is current

Article History

Accepted: 30 January 2026

First Online: 20 February 2026

Competing interests

: G.M. has received honoraria from Incyte, Pierre Fabre and Servier. S.N. has received personal fees from Novartis and a travel grant from Amgen. D.C. declares advisory board and/or consultancy roles for Bayer, Foundation Medicine and Merck, and travel support from Bristol Myers Squibb, Merck and Sanofi. E.M. has served as an adviser and speaker for AstraZeneca, Eisai, Eli Lilly, Merck, Pfizer, Roche, Sanofi/Genzyme and Servier outside the submitted work. T.T. has received travel grants from AstraZeneca and Pierre Fabre, and is an advisory board member for Amgen, AstraZeneca, Bayer, Merck, Pierre Fabre, Roche, Sanofi and Servier. M.G.Z. has received honoraria for advisory board roles from GSK. N.F. has received honoraria for consultancy and speaker roles from ITM Radiopharma and Novartis. G.C. has received speaker’s honoraria from Bristol Myers Squibb, Celltrion, Foundation Medicine, Lilly, MSD, NanoString, Novartis, Pfizer, Roche, Samsung and Seattle Genetics; honoraria for consultancy roles from NanoString, Roche and Seattle Genetics; honoraria for participating in advisory boards from Celltrion, Foundation Medicine, Lilly, Mylan, Pfizer, Roche and Samsung; honoraria for writing engagement from Bristol Myers Squibb and Novartis; honoraria for participation in the Ellipsis Scientific Affairs Group; and institutional research funding for conducting phase I and II clinical trials from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Janssen-Cilag, Medimmune, Medivation, Merck Serono, MSD, Novartis, Orion Therapeutics, Pfizer, Philogen, Roche, Sanofi, Seattle Genetics, Servier and Tesaro. F.C. has received institutional research grants from Amgen, Merck, MSD, Pfizer, Pierre Fabre, Roche and Servier; and has served on advisory boards for Bayer, Merck, MSD, Pierre Fabre, Roche and Servier. L.B.B. declares no competing interests.